Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene
Innovent Biologics Inc (1641475D HK)Â is the fourth pre-profit biotech firm to IPO in Hong Kong since Ascletis Pharma Inc (1672 HK), BeiGene Ltd...
847 Views
S&P 500: Outlook Constructive but Concerns Remain
As the S&P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we...
437 Views
U.S. Vital Signs - Actionable Charts of the Day
Today's key points: Property & Casualty Insurance names are staging price and RS reversal and/or breakouts. Airlines are staging price and SR...
533 Views
BAN2401 Detailed Data Presented at AAIC 2018 Validates Our Initial Concerns
Background - Eisai Co Ltd (4523 JP)Â on December 21, 2017, announced that 12 months data on BAN2401 did not meet its primary endpoint (link),...
545 Views
Merck Alliance Provides Stability to Deal With the Outcome of High Risk Alzheimer’s R&D in FY19
We upgrade Eisai Co Ltd (4523 JP) to “Equal-weight” after reviewing our model post FY17 (YE Mar-18) earnings, in light of the augmented peak sales...
342 Views